Edgewise Therapeutics, Inc. (EWTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$38.87+3.57%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · EWTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -29.2% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and its industry peers have been missing lately. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
EWTX — earnings miss
Dated 2026-08-06
and Item 9.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Why it matters: Edgewise reported a $2.01 billion pro forma cash balance before taxes and deal costs. Its Q2 net loss was $57.3 million as R&D spending rose.
Watch forThe November 5 report shows cash above $1.8 billion and R&D spending below $60 million for the quarter.
Also watch forThe report shows cash below $1.8 billion or R&D spending above $60 million for the quarter.
Why it matters: Starting the trial would move a second heart drug into patient testing. A delay would leave the pipeline more reliant on EDG-7500.
Supportive ifThe company announces that the EDG-15400 Phase 2 HFpEF trial has started by December 31, 2026.
Worry ifThe company says the Phase 2 start has moved beyond the second half of 2026.
Why it matters: A Q4 start would follow the plan set after positive 12-week CIRRUS-HCM data. A delay would slow the lead program.
Supportive ifThe company announces that the EDG-7500 Phase 3 trial has started by December 31, 2026.
Worry ifThe company says the trial will start after Q4 2026 or reports a delay.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$202 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $518 loss on $10,000 · 5.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,496 loss on $10,000 · 25.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.